Unknown

Dataset Information

0

N-Heterocyclic Carbene Capture by Cytochrome P450 3A4.


ABSTRACT: Cytochrome P450 3A4 (CYP3A4) is the dominant P450 enzyme involved in human drug metabolism, and its inhibition may result in adverse interactions or, conversely, favorably reduce the systemic elimination rates of poorly bioavailable drugs. Herein we describe a spectroscopic investigation of the interaction of CYP3A4 with N-methylritonavir, an analog of ritonavir, widely used as a pharmacoenhancer. In contrast to ritonavir, the binding affinity of N-methylritonavir for CYP3A4 is pH-dependent. At pH <7.4, the spectra are definitively type I, whereas at pH ?7.4 the spectra have split Soret bands, including a red-shifted component characteristic of a P450-carbene complex. Variable-pH UV-visible spectroscopy binding studies with molecular fragments narrows the source of this pH dependence to its N-methylthiazolium fragment. The C2 proton of this group is acidic, and variable-pH resonance Raman spectroscopy tentatively assigns it a pKa of 7.4. Hence, this fragment of N-methylritonavir is expected to be readily deprotonated under physiologic conditions to yield a thiazol-2-ylidene, which is an N-heterocyclic carbene that has high-affinity for and is presumed to be subsequently captured by the heme iron. This mechanism is supported by time-dependent density functional theory with an active site model that accurately reproduces distinguishing features of the experimental UV-visible spectra of N-methylritonavir bound to CYP3A4. Finally, density functional theory calculations support that this novel interaction is as strong as the tightest-binding azaheterocycles found in P450 inhibitors and could offer new avenues for inhibitor development.

SUBMITTER: Jennings GK 

PROVIDER: S-EPMC4931868 | biostudies-other | 2016 Jul

REPOSITORIES: biostudies-other

altmetric image

Publications

N-Heterocyclic Carbene Capture by Cytochrome P450 3A4.

Jennings Gareth K GK   Ritchie Caroline M CM   Shock Lisa S LS   Lyons Charles E CE   Hackett John C JC  

Molecular pharmacology 20160428 1


Cytochrome P450 3A4 (CYP3A4) is the dominant P450 enzyme involved in human drug metabolism, and its inhibition may result in adverse interactions or, conversely, favorably reduce the systemic elimination rates of poorly bioavailable drugs. Herein we describe a spectroscopic investigation of the interaction of CYP3A4 with N-methylritonavir, an analog of ritonavir, widely used as a pharmacoenhancer. In contrast to ritonavir, the binding affinity of N-methylritonavir for CYP3A4 is pH-dependent. At  ...[more]

Similar Datasets

| S-EPMC7948456 | biostudies-literature
| S-EPMC5857991 | biostudies-literature
| S-EPMC3099659 | biostudies-literature
| S-EPMC6433705 | biostudies-literature
| S-EPMC1564212 | biostudies-literature
| S-EPMC3310418 | biostudies-literature
| S-EPMC4532289 | biostudies-literature
| S-EPMC5255590 | biostudies-literature
| S-EPMC3862586 | biostudies-literature
| S-EPMC6272561 | biostudies-literature